

# Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: ☐ Medicare Part B ☒ Medicare Part D  
 This request is: ☐ Expedited request ☐ Standard request

Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting.

## Neupogen<sup>®</sup> (filgrastim)

### Member

Last Name: \_\_\_\_\_ First Name: \_\_\_\_\_  
 ID #: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Primary Care Physician: \_\_\_\_\_  
 Requesting Provider: \_\_\_\_\_ Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_  
 Provider Address: \_\_\_\_\_  
 Provider NPI: \_\_\_\_\_ Contact Name: \_\_\_\_\_  
 Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_

### Product Information

☐ New request ☐ Continuation request

Drug product: ☐ Neupogen 300 mcg vial **Start date** (or date of next dose): \_\_\_\_\_  
☐ Neupogen 480 mcg vial **Date of last dose** (if applicable): \_\_\_\_\_  
☐ Neupogen 300 mcg SingleJect syringe **Dosing frequency:** \_\_\_\_\_  
☐ Neupogen 480 mcg SingleJect syringe

### Priority Health Precertification Documentation

A. Will this drug be self-administered? ☐ Yes ☐ No

B. Must be used for a medically-accepted indication\*

What condition is this drug being requested for?

- |                                                                    |                                                                 |
|--------------------------------------------------------------------|-----------------------------------------------------------------|
| <input type="checkbox"/> Agranulocytosis                           | <input type="checkbox"/> Leukemia                               |
| <input type="checkbox"/> AIDS-related neutropenia                  | <input type="checkbox"/> Mucositis following chemotherapy       |
| <input type="checkbox"/> Aplastic anemia                           | <input type="checkbox"/> Myelodysplastic syndrome               |
| <input type="checkbox"/> Febrile neutropenia                       | <input type="checkbox"/> Neutropenia due to pre-eclampsia       |
| <input type="checkbox"/> Severe, chronic neutropenia               | <input type="checkbox"/> Harvesting peripheral blood stem cells |
| <input type="checkbox"/> Infectious disease prophylaxis            |                                                                 |
| <input type="checkbox"/> Other – the patient's condition is: _____ |                                                                 |

---

**Medically accepted indication\***

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*:

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- — or — supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information and the DRUGDEX Information System)

---

**Priority Health Medicare exception request**

**Do you believe one or more of the prior authorization requirements should be waived?** ☐ Yes ☐ No

If yes, you must provide a statement explaining the medical reason why the exception should be approved.

**Would Neupogen likely be the most effective option for this patient?**

☐ No

☐ Yes, because: \_\_\_\_\_

**If the patient is currently using Neupogen, would changing the patient's current regimen likely result in adverse effects for the patient?**

☐ No

☐ Yes, because: \_\_\_\_\_